The former meta-analysis lacked any data on the safety profile of SGLT2 inhibitors as well as functional and structural heart parameters like NT-pro BNP and LVEF, which are crucial for understanding the impact of SGLT2 inhibitors on cardiac remodeling post-myocardial infarction[33]. The gene discussed is NPPB; the disease is myocardial infarction.